US-based biotech company, Banyan Biomarkers, Inc. has developed the first blood test that can be used by physicians to objectively aid in the evaluation of patients with suspected traumatic brain injury (TBI) or concussions. The Banyan Brain Trauma Indicator® (Banyan BTI™) consists of two diagnostic test kits, Banyan UCH-L1® Kit and Banyan GFAP® Kit, which measure two specific protein biomarkers that rapidly appear in the blood after a brain injury. According to the developers, the Banyan BTI can be used to rule out the need for a head CT scan in patients 18 years of age and older with a suspected TBI. This blood test could play an important role in public health where there’s a need to reduce the number of unnecessary CT scans and their associated costs, particularly among those with mild concussions. Banyan Biomarkers recently announced the publication of the results for the ALERT-TBI study, an international, multicentre clinical trial utilising the Banyan BTI. The results, which were published in The Lancet Neurology, support the clinical role of the biomarker test for ruling out the need for a head CT scan among emergency department TBI patients who would normally receive a head CT scan.